<code id='70F0660C00'></code><style id='70F0660C00'></style>
      • <acronym id='70F0660C00'></acronym>
      <center id='70F0660C00'><center id='70F0660C00'><tfoot id='70F0660C00'></tfoot></center><abbr id='70F0660C00'><dir id='70F0660C00'><tfoot id='70F0660C00'></tfoot><noframes id='70F0660C00'>
      • <optgroup id='70F0660C00'><strike id='70F0660C00'><sup id='70F0660C00'></sup></strike><code id='70F0660C00'></code></optgroup>
        5. <b id='70F0660C00'><label id='70F0660C00'><select id='70F0660C00'><dt id='70F0660C00'><span id='70F0660C00'></span></dt></select></label></b><u id='70F0660C00'></u>
          <i id='70F0660C00'><strike id='70F0660C00'><tt id='70F0660C00'><pre id='70F0660C00'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / entertainment / entertainment      
           
     
           
      
          entertainment 
           
      
           
      
           
       2025-09-27 20:09:45 
   
      
           
      
           
                        
          entertainment  
          
                                   
                 
                                      author：knowledge   
                                        
                                      
                                      Page View：23
                                  
                                    
          
                                   
          Dozens of sickle cells in a whirlpool — coverage from STAT
          Adobe
          Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes. 
          The document was supposed to help Novak, then the chief executive of CRISPR Therapeutics, navigate a pressing quandary. His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9, which promised to cure numerous genetic diseases. But which should they target first? What was the best proof-of-concept?
          advertisement
          “We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year. 
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)
                                
                            
          Next article：  
                                      
                                          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles